138 related articles for article (PubMed ID: 10533477)
41. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
Liu DW; Tsao YP; Kung JT; Ding YA; Sytwu HK; Xiao X; Chen SL
J Virol; 2000 Mar; 74(6):2888-94. PubMed ID: 10684306
[TBL] [Abstract][Full Text] [Related]
42. [Immunogenicity of mutant and wild HPV16 DNA vaccines].
Zuo YG; Wang JB; Jin HZ; Yue-hua L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Oct; 26(5):554-7. PubMed ID: 15562771
[TBL] [Abstract][Full Text] [Related]
43. Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7.
Chu NR; Wu HB; Wu TC; Boux LJ; Mizzen LA; Siegel MI
Cell Stress Chaperones; 2000 Nov; 5(5):401-5. PubMed ID: 11189443
[TBL] [Abstract][Full Text] [Related]
44. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.
Welters MJ; van der Sluis TC; van Meir H; Loof NM; van Ham VJ; van Duikeren S; Santegoets SJ; Arens R; de Kam ML; Cohen AF; van Poelgeest MI; Kenter GG; Kroep JR; Burggraaf J; Melief CJ; van der Burg SH
Sci Transl Med; 2016 Apr; 8(334):334ra52. PubMed ID: 27075626
[TBL] [Abstract][Full Text] [Related]
45. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope.
Alexander M; Salgaller ML; Celis E; Sette A; Barnes WA; Rosenberg SA; Steller MA
Am J Obstet Gynecol; 1996 Dec; 175(6):1586-93. PubMed ID: 8987945
[TBL] [Abstract][Full Text] [Related]
46. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers.
Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E
Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206
[TBL] [Abstract][Full Text] [Related]
47. Vaccines against human papillomavirus and cervical cancer: promises and challenges.
Mahdavi A; Monk BJ
Oncologist; 2005 Aug; 10(7):528-38. PubMed ID: 16079320
[TBL] [Abstract][Full Text] [Related]
48. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination.
Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM
Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558
[TBL] [Abstract][Full Text] [Related]
49. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III.
Nimako M; Fiander AN; Wilkinson GW; Borysiewicz LK; Man S
Cancer Res; 1997 Nov; 57(21):4855-61. PubMed ID: 9354449
[TBL] [Abstract][Full Text] [Related]
50. Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines.
Talebi S; Bolhassani A; Azad TM; Arashkia A; Modaresi MH
Protein Pept Lett; 2017; 24(3):190-196. PubMed ID: 28000571
[TBL] [Abstract][Full Text] [Related]
51. A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.
Tindle RW; Croft S; Herd K; Malcolm K; Geczy AF; Stewart T; Fernando GJ
Clin Exp Immunol; 1995 Aug; 101(2):265-71. PubMed ID: 7544248
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide.
Weijzen S; Meredith SC; Velders MP; Elmishad AG; Schreiber H; Kast WM
J Immunol; 2001 Jun; 166(12):7151-7. PubMed ID: 11390461
[TBL] [Abstract][Full Text] [Related]
53. Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia.
van den Hende M; van Poelgeest MI; van der Hulst JM; de Jong J; Drijfhout JW; Fleuren GJ; Valentijn AR; Wafelman AR; Slappendel GM; Melief CJ; Offringa R; van der Burg SH; Kenter GG
Int J Cancer; 2008 Jul; 123(1):146-52. PubMed ID: 18404684
[TBL] [Abstract][Full Text] [Related]
54. Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination.
Kibur M; af Geijerstamm V; Pukkala E; Koskela P; Luostarinen T; Paavonen J; Schiller J; Wang Z; Dillner J; Lehtinen M
Sex Transm Infect; 2000 Feb; 76(1):13-7. PubMed ID: 10817062
[TBL] [Abstract][Full Text] [Related]
55. Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer.
Höhn H; Pilch H; Günzel S; Neukirch C; Freitag K; Necker A; Maeurer MJ
J Virol; 2000 Jul; 74(14):6632-6. PubMed ID: 10864677
[TBL] [Abstract][Full Text] [Related]
56. Immunization and immunotherapy for cancers involving infection by a human papillomavirus in a mouse model.
Li J; Sun Y; Garen A
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16232-6. PubMed ID: 12446839
[TBL] [Abstract][Full Text] [Related]
57. Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine.
Franconi R; Massa S; Illiano E; Mullar A; Cirilli A; Accardi L; Di Bonito P; Giorgi C; Venuti A
Int J Immunopathol Pharmacol; 2006; 19(1):187-97. PubMed ID: 16569357
[TBL] [Abstract][Full Text] [Related]
58. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
Ohlschläger P; Osen W; Dell K; Faath S; Garcea RL; Jochmus I; Müller M; Pawlita M; Schäfer K; Sehr P; Staib C; Sutter G; Gissmann L
J Virol; 2003 Apr; 77(8):4635-45. PubMed ID: 12663770
[TBL] [Abstract][Full Text] [Related]
59. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
Mohit E; Bolhassani A; Zahedifard F; Taslimi Y; Rafati S
Scand J Immunol; 2012 Jan; 75(1):27-37. PubMed ID: 21916914
[TBL] [Abstract][Full Text] [Related]
60. Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2].
Takeuchi S; Kagabu M; Shoji T; Nitta Y; Sugiyama T; Sato J; Nakamura Y
Oncoimmunology; 2020 Nov; 9(1):1838189. PubMed ID: 33235818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]